Table 2. Summary of overall and subgroup analyses of the association between folic acid treatment and colorectal cancer risk.
CRC incidents | |||||||
---|---|---|---|---|---|---|---|
Stratification variablesa | Active | Control | RR (95% CI) | Z | P> | Ph | I2(%) |
Total population | 191 | 190 | 1.00 (0.82–1.22) | 0.03 | 0.974 | 0.821 | <0.001 |
Ethnicity | |||||||
Caucasian | 115 | 126 | 0.91 (0.71–1.17) | 0.73 | 0.463 | 0.807 | <0.001 |
Mixed | 74 | 62 | 1.19 (0.85–1.67) | 1.03 | 0.303 | 0.578 | <0.001 |
Total | 189 | 188 | 1.00 (0.82–1.23) | 0.03 | 0.974 | 0.727 | <0.001 |
Age (year)b | |||||||
<mean20,22,24,26 | 109 | 119 | 0.92 (0.71–1.19) | 0.67 | 0.501 | 0.967 | <0.001 |
>mean19,23 | 51 | 40 | 1.28 (0.85–1.93) | 1.17 | 0.243 | 0.227 | 31.4 |
Total | 160 | 159 | 1.01 (0.81–1.25) | 0.05 | 0.957 | 0.605 | <0.001 |
Male (%)b | |||||||
<mean22,23,25 | 22 | 27 | 0.78 (0.44–1.37) | 0.87 | 0.384 | 0.724 | <0.001 |
>mean19,20,24,25 | 160 | 153 | 1.05 (0.84–1.30) | 0.39 | 0.694 | 0.542 | <0.001 |
Total | 182 | 180 | 1.01 (0.82–1.23) | 0.05 | 0.962 | 0.727 | <0.001 |
BMI (kg/m2 b | |||||||
<mean20,23 | 4 | 7 | 0.56 (0.17–1.91) | 0.92 | 0.355 | 0.561 | <0.001 |
>mean19,22 | 68 | 59 | 1.15 (0.82–1.63) | 0.81 | 0.417 | 0.188 | 42.3 |
Total | 72 | 66 | 1.09 (0.78–1.52) | 0.51 | 0.608 | 0.364 | 5.9 |
Dose of folic acidb | |||||||
<mean20,21,23,24,26 | 102 | 110 | 0.92 (0.71–1.21) | 0.58 | 0.562 | 0.919 | <0.001 |
>mean19,22,25 | 89 | 80 | 1.11 (0.82–1.50) | 0.70 | 0.485 | 0.386 | <0.001 |
Total | 191 | 190 | 1.00 (0.82–1.22) | 0.03 | 0.974 | 0.821 | <0.001 |
Durationb | |||||||
<mean19,21,23,25,26 | 84 | 73 | 1.15 (0.84–1.57) | 0.86 | 0.389 | 0.711 | <0.001 |
>mean20,22,24 | 107 | 117 | 0.91 (0.70–1.19) | 0.68 | 0.497 | 0.881 | <0.001 |
Total | 191 | 190 | 1.00 (0.82–1.22) | 0.03 | 0.974 | 0.821 | <0.001 |
Prior Disease | |||||||
Colorectal adenoma19,20,23 | 14 | 17 | 0.81 (0.40–1.62) | 0.61 | 0.544 | 0.669 | <0.001 |
CVD19,22,24,25 | 175 | 171 | 1.02 (0.83–1.26) | 0.22 | 0.829 | 0.477 | <0.001 |
Possible confounding factors | |||||||
Vitamin19,20,22,23,24,25 | 179 | 178 | 1.01 (0.82–1.24) | 0.05 | 0.962 | 0.605 | <0.001 |
Antiplatelet drugs19,20,21,23,25 | 85 | 75 | 1.13 (0.83–1.54) | 0.77 | 0.442 | 0.653 | <0.001 |
Lipid-lowering drugs19,24 | 136 | 128 | 1.06 (0.84–1.35) | 0.50 | 0.617 | 0.169 | 47.1 |
Alcohol20,22,23,25,26 | 45 | 52 | 0.86 (0.58–1.28) | 0.73 | 0.466 | 0.908 | <0.001 |
Diabetes19,22,24,25 | 175 | 171 | 1.02 (0.83–1.26) | 0.22 | 0.829 | 0.477 | <0.001 |
Current smoker19,20,22,26 | 181 | 180 | 1.01 (0.82–1.23) | 0.05 | 0.962 | 0.727 | <0.001 |
Hypertension19,22,24 | 154 | 150 | 1.03 (0.82–1.28) | 0.23 | 0.814 | 0.289 | 19.4 |
CVD, cardiovascular disease; CRC, colorectal cancer.
P, P value for association.
Ph, P value for heterogeneity.
aonly articles reporting the variables were analyzed.
bweighted mean of included articles.